The Mayo Clinic Breast Cancer SPORE will maximize the number of innovative and high-quality projects in the Developmental Research Program. The goal of this program is to support innovative, scientifically meritorious research projects from which findings can be translated into clinically important applications that will impact diagnosis and management of breast cancer in order to decrease the burden and mortality from this disease. This program will: 1) encourage and solicit innovative translational laboratory, population, and clinical study proposals;2) encourage and support interdisciplinary collaboration in translational research in breast cancer;and 3) generate new hypotheses that can be tested in larger-scale research projects or clinical trials that can impact breast cancer. The availability of this support provides a stimulus for creativity in the research community, a vehicle for encouraging the interaction of basic scientists and translational investigators, and an opportunity for expanding the research spectrum of the SPORE by pursuing new leads based on discoveries and/or opportunities that arise. The Developmental Research Program will provide $50,000 for one year ($25,000 from SPORE funds and a matching $25,000 from Mayo Clinic Cancer Center) to each of six projects. There will be the possibility of a second year of support based on demonstration of sufficient progress. A process was established during the initial grant for the Mayo Clinic Breast Cancer SPORE involving a call for applications on an annual basis and a formal peer review utilizing the expertise of the Internal Scientific Advisory Committee and other experienced investigators. Because of the success of this process, it will be continued. Criteria for selection of projects for funding are based upon scientific merit, originality, qualifications of the applicant, and translational potential. It is expected that support of developmental research projects will result in generation of data that will serve as the basis for additional SPORE-sponsored projects or support through peer reviewed external grant support. It is the intent of the SPORE leadership to encourage and help the investigators to use the data generated by these projects to establish preclinical or clinical trials in breast cancer. In addition the SPORE leadership will work with the investigators to secure independent R01-level funding. Two of the four full Projects in this SPORE renewal have a co-leader who was a Developmental Research Program awardee, which indicates that the Developmental Research Program has been successful in this regard during the previous funding period.

Public Health Relevance

The Developmental Research Program supports innovative and scientifically meritorious research projects that have the greatest potential to be translated into clinically important applications for the prevention, diagnosis and treatment of women with breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116201-08
Application #
8744966
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2013-09-01
Project End
2016-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
8
Fiscal Year
2013
Total Cost
$207,988
Indirect Cost
$64,816
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Leontovich, Alexey A; Jalalirad, Mohammad; Salisbury, Jeffrey L et al. (2018) NOTCH3 expression is linked to breast cancer seeding and distant metastasis. Breast Cancer Res 20:105
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
Augusto, Bianca; Kasting, Monica L; Couch, Fergus J et al. (2018) Current Approaches to Cancer Genetic Counseling Services for Spanish-Speaking Patients. J Immigr Minor Health :
Supekar, Nitin T; Lakshminarayanan, Vani; Capicciotti, Chantelle J et al. (2018) Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. Chembiochem 19:121-125
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Fasching, Peter A; Loibl, Sibylle; Hu, Chunling et al. (2018) BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 36:2281-2287
Rice, Megan S; Tamimi, Rulla M; Bertrand, Kimberly A et al. (2018) Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Res Treat 170:129-141
Wang, Liewei; Ingle, James; Weinshilboum, Richard (2018) Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study. Clin Pharmacol Ther 103:243-252
Augusto, Bianca M; Lake, Paige; Scherr, Courtney L et al. (2018) From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals. J Community Genet 9:209-215

Showing the most recent 10 out of 473 publications